IKT vs TDG · $215.2M cap vs P/E 41, rev $8.83B
Inhibikase Therapeutics Inc (IKT) versus Transdigm Group Incorporated (TDG) — a side-by-side from cached financials, not a winner call.
Inhibikase Therapeutics Inc (IKT) is a biotechnology company listed on US.
Transdigm Group Incorporated (TDG) is a aerospace & defense company listed on NYSE.
Latest reported IKT revenue for 2026-06-30 was $0. Net income was -$36.0M. IKT currently screens at market cap $215.2M.
Latest reported TDG revenue for 2025-09-30 was $8.83B. Net income was $2.07B. TDG currently screens at market cap $73.65B and trailing P/E 41.1.
IKT currently screens at market cap $215.2M. TDG currently screens at market cap $73.65B and trailing P/E 41.1.
Not investment advice. Open the IKT and TDG stock pages for the full models.
Not investment advice.